R-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: R-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine
• 英文别名: R-edelfosine；R-AP-121；edelfosine；2-[hydroxy-[(2R)-2-methoxy-3-octadecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
• 化学式: C₂₇H₅₉NO₆P
• 分子量: 524.742
• InChiKey: MHFRGQHAERHWKZ-HHHXNRCGSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  35
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine 在 Chiralpak IC 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 R-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine 、 S-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine
  参考文献：
  名称：

  [EN] S-ENANTIOMER OF A TRI-SUBSTITUTED GLYCEROL COMPOUND
  [FR] ENANTIOMÈRE S D'UN COMPOSÉ GLYCÉROL TRI-SUBSTITUÉ

  摘要：

  本发明涉及三取代甘油化合物的S-对映体。本发明还涉及包含该化合物或其药学上可接受的盐的制药组合物。此外，本发明还涉及将AP-121对映体的混合物分离成S-对映体和R-对映体的方法。

  公开号：

  WO2013156630A1

文献信息

• METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS
  申请人：Quay C. Steven

  公开号：US20070077283A1

  公开（公告）日：2007-04-05

  A composition comprising a biologically active agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive a platelet activating factor, and increases permeability of the biologically active agent across a tissue layer. Also disclosed is a process of increasing the permeability of a biological agent across a layer tissue comprising contacting the tissue layer with a composition comprising the biological agent and a permeation enhancing lipid wherein the permeation enhancing lipid is a platelet activating factor antagonist or a biologically inactive platelet activating factor.
• METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE
  申请人：Jordt Sven-Eric

  公开号：US20110144137A1

  公开（公告）日：2011-06-16

  The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical noxious effects of toxicants, including but not limited to, tear gases, chlorine, hydrogen peroxide, ammonia, phosgene, chloropicrin, isocyanates and mustard gas. Administering the counteragents counteracts pain, inflammation, lachrymation, blepharospasm, respiratory irritation and depression, airway mucus secretion, airway obstruction and injury, cough and incapacitation and cutaneous chemical injuries. Another embodiment provides a method of preventing or treating a disease or condition in a mammal, which disease or condition includes hypersensitivity to chemical stimuli, particularly in regards to inflammatory airway conditions, such as asthma, rhinitis, etc., by administering to the mammal a therapeutically effective amount of a compound that inhibits TRPA1 function, wherein the compound reduces the hypersensitivity and mediates the response to such chemical stimuli in the mammal. The invention also includes a kit containing the compound that inhibits the TRPA1 function as a counteracting agent for administration prior to or post exposure to prevent or limit the effects of the exposure.